Ophthalmology entrepreneur based in Barcelona that led the foundation of AVX Pharma in 2013 and has been key in securing both financing and a strong team to bring AVX Pharma lead candidate AVX-012 into clinical development and drive the company at the forefront of innovation in Dry Eye Syndrome.
Professor Carlos Belmonte obtained his MD and PhD degree at the University of Madrid, Spain. He is presently Professor of Human Physiology at the Medical School, University Miguel Hernandez and senior researcher of the Neurosciences Institute of Alicante. He is ex-President of the International Brain Research Organization, member of the Academia Europaea and of the National Academy of Sciences of Spain and Doctor Honoris Causa of the University of Castilla la Mancha. He has been Director of the Department of Physiology and Vice-dean at the Medical School, University of Valladolid and served as Vice President for Academic Affairs and as Dean of the Medical School at the University of Alicante upon its foundation. He created and directed the Department of Physiology at the University of Alicante, and in 1990 the Institute of Neurosciences, a Joint Center of the National Research Council (CSIC) and the University Miguel Hernandez, that he directed continuously until his voluntary resignation in 2007.He has been Visiting Professor at the Universities of Harvard and Utah, Adjunt Professor of Ophthalmology of the University of Utah, the Eye Research Institute of the Retina Foundation and Visiting Scientist at the Prince of Wales Medical Research Institute of New South Wales University in Australia. Professor Carlos Belmonte has been awarded in Spain with the National Research Award “Rey Jaime I”, the National Prize for Biology and Biomedicine “Severo Ochoa” and the National Award in Medicine “Gregorio Marañón” among others and with the Endre Balazs Prize of the International Society for Eye Research, the European Vision Award of the European Vision Institute, Special Honoree of the ARVO Fundation for his outstanding contribution to vision and ophtalmology. Professor Belmonte is an internationally recognized expert in neurosciences, particularly in ocular innervation and pain and is the autor of more that 150 scientifc articles and 20 book chapters.
Dr. Galán was Director of Pharmaceutical Development Group Barcelona (BCN) at Alcon Laboratories until 2012. His main tasks and contributions for the last 20 years at Alcon have been overseeing all pharmaceutical development activities (Formulation, A. Chemistry, Process Development, Stability Systems and Technology Transfer Departments) for projects assigned to the Barcelona R&D group, with direct reporting to Global Headquarters in Fort Worth, TX. Javier managed a wide range of projects including early stage (exploratory) studies, Proof of Concept and Confirmatory Phase, submission, approval and Post-marketing support. He had a a key participation in new technologies/innovation assessment on formulations (internal/external) at Corporate level, and also IP evaluation, being Responsible for “Ideation/new technologies” projects on ENT pharmaceutical formulated products. Dr. Javier Galán is an expert in Speciality Ophthalmic Drug Delivery Technologies.
Jordi is a Graduate in Business Administration and Master in Business Administration (MBA) by ESADE Management School (Barcelona) and Master Community of European Management Schools (CEMS) by the Ecole Hautes Etudes Commerciales, HEC (Paris).
His professional experience began in 1989 as CFO of Betne SA, publishing company, and as a founding partner and CFO of BPMO Edigroup SL. After working in 1992 in Bull Europe (Paris) in the Management Control area, he joined KPMG where he worked in Auditing and in Corporate Finance from 1994 to 1996.
Afterward he joined Acordis Acrylic Fibers, the first two years as Assistant to the Financial & Management Controller, becoming Controller in 1998.
In 2000, Jordi joined La Caixa, initially Caixa Holding, SA as Head of Controlling and Corporate Development for the business sector, and later as an Investment Director in Caixa Capital Risc, SGECR SA (venture capital firm of “la Caixa”) until 2007.
From 2007 until 2011 he was CFO of Oryzon Genomics, SA.
Additionally, from September 2000 until June 2003 he combined his professional career with teaching experience as Professor of the Management Control course at the Faculty of Business Administration (ADE), IQS (Barcelona).
Jordi is Partner at Vantum Corporate.